Conduit Pharmaceuticals Inc (CDT) Stock Trading Recap
On Monday, Conduit Pharmaceuticals Inc (CDT) stock saw a decline, ending the day at $0.12 which represents a decrease of $-0.01 or -7.69% from the prior close of $0.13. The stock opened at $0.13 and touched a low of $0.12 during the day, reaching a high of $0.13. The volume of shares traded was 3.67 million falling short of the average volume of 12.99 million.
Sponsored
CDT Stock Performance and Moving Averages
In recent trading, Conduit Pharmaceuticals Inc (CDT) stock price has shown some volatility, fluctuating -6.18% over the last five trades and -8.92% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -96.62%, and it has plunged by -88.09% in the previous three months. Currently, CDT is trading at -8.99%, -27.99%, and -94.83% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, CDT, a Healthcare sector stock, is trading -98.65% below its 52-week high but remains 5.24% above its 52-week low. The Average True Range (ATR) (14 days) of 0.02 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Conduit Pharmaceuticals Inc’s Profitability and Valuation Ratios
Conduit Pharmaceuticals Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -96.62%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Conduit Pharmaceuticals Inc’s market capitalization stands at $11.38 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 59.28% of Conduit Pharmaceuticals Inc (CDT)’s shares, while financial institutions hold 3.05%.
Notable insider trades include Regan Andrew, Director at Conduit Pharmaceuticals Inc (CDT), who sold 10244392 shares on Jul 16 ’24, at $0.32 each, totaling $3.25 million. On Jul 17 ’24, Regan Andrew, Director, sold 1514100 shares for $0.26 each, amounting to $0.39 million. Additionally, on Jul 12 ’24, Regan Andrew sold 1389820 shares at $0.25 each, generating $0.34 million.
